Business Wire

Celltrion Healthcare Presents Efficacy and Safety Data From Global Phase III LIBERTY Trial, at the 18th ECCO Congress

Share

Today, Celltrion Healthcare presented new data demonstrating the efficacy and safety of subcutaneous (SC) infliximab (CT-P13 SC) in patients with inflammatory bowel disease (IBD). The data were presented in a digital oral presentation and poster presentations at the 18th European Crohn’s and Colitis Organisation (ECCO) annual congress, in Copenhagen, Denmark.

CT-P13 SC LIBERTY Studies

LIBERTY-CD and LIBERTY-UC were randomized, placebo-controlled, double-blind, Phase III studies designed to evaluate the superiority of the subcutaneous CT-P13 (CT-P13 SC) in efficacy and safety during maintenance therapy for patients with Crohn’s disease (CD) and ulcerative colitis (UC), respectively.1,2

In the CT-P13 SC LIBERTY-CD study, a total of 343 patients were randomized in a 2:1 ratio at Week 10. At Week 54, the clinical remission rate was greater in the CT-P13 SC arm than the placebo arm (62.3% and 32.1% respectively, P<0.0001). In the CT-P13 SC LIBERTY-UC study, a total of 438 patients were randomized at Week 10. The rate of clinical remission at Week 54 was significantly greater in CT- P13 SC (43.2%) compared to the placebo (20.8%) (P<0.0001). The safety profile during the maintenance phase was comparable between CT-P13 SC and the placebo arms for both studies.

"These latest findings add to the growing body of evidence that supports the SC formulation of infliximab as a convenient and effective solution for treating IBD,” said Professor Jean Frédéric Colombel, Icahn School of Medicine at Mount Sinai, New York and presenting author of the digital oral presentation. “These results demonstrate that maintenance therapy with CT-P13 SC provides a robust clinical benefit, with the convenience of SC administration, for patients with moderately to severely active CD and UC.”

“The positive global Phase III LIBERTY studies have allowed us submit CT-P13 SC to the FDA as a stand-alone Biologics License Application under the 351 (a) pathway and the results have also reinforced our conviction in the value of CT-P13 SC,” said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare. “We believe that CT-P13 SC, if approved in the U.S., has the potential to become the next-generation innovative therapeutic for IBD given its favorable clinical results and convenient subcutaneous route of administration.”

CT-P13 SC PHASE I POST-HOC ANALYSIS AND REAL-WORLD CASE STUDIES

A separate post-hoc analysis of the randomised Phase I CT-P13 SC study data showed Ctrough level predicted anti-drug antibody (ADA) and neutralizing antibody (NAb) positivity in CD and UC patients, with a Ctrough threshold of 4.695 μg/mL significantly associated with lower rates of ADA and NAb positivity.3

In addition, real-world case studies presented during a satellite symposium at the ECCO congress indicate that reintroduction of infliximab may be a viable treatment option for CD patients with previous anti-TNF treatment failure, by aiming to reach a higher pharmacokinetics level and lower anti-drug antibody levels. Interim results of a pilot study suggest that SC infliximab may be a viable treatment option for patients with refractory CD.4

"Whilst there have been numerous recent advancements in IBD treatment options, there remains a pressing demand to address unmet medical need, especially for refractory IBD patients,” said Professor Milan Lukas, ISCARE and Charles University, Czech Republic, and one of the leading presenters for the satellite symposium. “These exploratory results suggest that SC infliximab could provide healthcare providers with a powerful treatment tool for CD patients who have previously been considered difficult to treat.”

- ENDS -

Notes to Editors:

About subcutaneous (SC) formulation of CT-P13

CT-P13 SC is the world’s first subcutaneous formulation of infliximab. A 120 mg fixed dose of CT-P13 SC has been approved for use in the European Union (EU), in adults regardless of body weight, in both existing and newly added indications. The SC formulation has the potential to enhance treatment options for the use of the infliximab drug by providing high consistency in drug exposure and a convenient method of administration.5,6

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA Current Good Manufacturing Practice (cGMP) and EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality, cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information, please visit: https://www.celltrionhealthcare.com/en-us/

About inflammatory bowel disease

Inflammatory bowel diseases (IBDs), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic, disabling gastrointestinal disorders that can significantly impact patients’ lives.7 They affect an estimated 10 million people globally.8 IBDs account for substantial costs to the healthcare system and society - the direct healthcare costs of IBDs are estimated to be €4.6-5.6 billion per year.9

FORWARD-LOOKING STATEMENT

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion/Celltrion Healthcare that may constitute forward-looking statements, under pertinent securities laws.

These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion/Celltrion Healthcare's management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of Celltrion/Celltrion Healthcare believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion/Celltrion Healthcare undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

References

1 Jean F. Colombel et al., Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: A Phase 3, randomised, placebo-controlled study (LIBERTY-CD). Digital Oral Presentation (DOP86). Presented at ECCO 2023.
2 Bruce E. Sands et al., Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A Phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC study. Poster (P492). Presented at ECCO 2023.
3 Stefan Schreiber et al., Predictors of immunogenicity in patients with inflammatory bowel disease treated with infliximab: A post hoc analysis of the randomised Phase I CT-P13 SC study. Poster (P524). Presented at ECCO 2023.
4 Lukas M et al. Infliximab CT P13 SC in refractory Crohn's disease patients preliminary results of a pilot project Poster (P030). Presented at Crohn’s and Colitis Congress 2023.
5 A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase I open-label randomised controlled trial in patients with active Crohn’s disease, Journal of Crohn's and Colitis, Volume 13, Issue Supplement_1, March 2019, Pages S066–S067, https://doi.org/10.1093/ecco-jcc/jjy222.096 [Last accessed February 2023].
6 R.Westhovens et al. A Novel Formulation of CT-P13 (Infliximab Biosimilar) for Subcutaneous Administration: 30-week Results from Part Two of a Phase I/III Randomised Controlled Trial in Patients with Rheumatoid Arthritis. Poster (SAT0170) Presented at EULAR 2019
7 Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 142(1), 46-54. Retrieved from: www.gastrojournal.org/article/S0016-5085(11)01378-3/pdf [Last accessed February 2023].
8 The European Federation of Crohn’s & Ulcerative Colitis Associations. What is IBD? Science. Retrieved from www.efcca.org/content/what-ibd [Last accessed February 2023].
9 The burden of inflammatory bowel disease in Europe. Journal of Crohn's and Colitis, 7(4), 322-337. Retrieved from: www.sciencedirect.com/science/article/pii/S1873994613000305?via%3Dihub [Last accessed February 2023].

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Iris Shaffer
ishaffer@apcoworldwide.com
+1 708-297-1712

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Spot by NetApp Survey Highlights the Enterprise-Wide Importance of CloudOps and Identifies Key Challenges for Cloud Teams to Achieve Success7.6.2023 15:00:00 EEST | Press release

NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today released its 2023 State of CloudOps report, an annual survey exploring the current state of CloudOps and how IT decision makers feel about the ways their organizations are working to optimize their environments. The report found that only 33% of executives are “very confident” in their ability to operate in a public cloud environment, an increase from 2022 when only 21% reported feeling very confident. “Cloud operations is critical to realizing the benefits of cloud for infrastructure and applications,” said Haiyan Song, Executive Vice President and General Manager, CloudOps at NetApp. “This research demonstrates that although organizations face challenges in their cloud operations, they also recognize the importance of investments in areas including automation and FinOps to overcome those challenges.” Key Findings from Spot by NetApp’s 2023 State of CloudOps Report: Cloud operations remain a struggle for

PPG’s New Paint for a New Start initiative to beautify schools worldwide with colorful makeovers7.6.2023 15:00:00 EEST | Press release

PPG (NYSE:PPG) today announced that it will dedicate June, July and August 2023 to completing more than 25 colorful and transformative school makeovers worldwide through its New Paint for a New Start initiative, part of the company’s COLORFUL COMMUNITIES® program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005072/en/ In June, July and August 2023, PPG employees worldwide will transform learning environments and create transformative school makeovers through the New Paint for a New Start initiative. (Photo: Business Wire) In the second year of New Paint for a New Start, PPG employees will volunteer their time to transform learning environments. Using PPG paint products and color expertise, each project aims to create engaging spaces for students to learn and grow. “PPG employees from every region are coming together once again to protect and beautify schools and learning spaces and inspire bright starts for students

Organon and CAF, Development Bank of Latin America, Launch First-of-Its-Kind Collaboration to Increase Sustainable Financing in Women’s Health7.6.2023 14:30:00 EEST | Press release

Today, Organon (NYSE:OGN), a global healthcare company focused on women’s health, and CAF, Development Bank of Latin America, signed a memorandum of understanding (MOU) to contribute to the United Nations Sustainable Development Goals through the design, structure and implementation of sustainable programs that promote and improve equity, health and autonomy of girls and women in Latin America and the Caribbean. Across the globe, tremendous gaps exist in women’s health that can potentially prevent women and thus economies from achieving their full potential. Sustainable financing can advance progress in women’s health by mobilizing capital towards initiatives that might not otherwise receive adequate support like increasing access to sexual and reproductive health education and healthcare services. Sustainable financing is one potential solution to address constrained government budgets while catalyzing healthcarei and socioeconomic progress. Health-focused social impact investments –

Falcon 40B: World’s Top AI Model Rewards Most Creative Use Cases in Call for Proposals with Training Compute Power7.6.2023 13:21:00 EEST | Press release

Falcon 40B, the world’s top-ranked open-source AI model on the Hugging Face leaderboard for large language models (LLMs), is registering an overwhelming response to a Call for Proposals from scientists, researchers, and SME entrepreneurs keen to deploy the model for innovative use cases. The response follows back-to-back announcements from the AI model’s creator, Abu Dhabi’s Technology Innovation Institute (TII), offering the most exceptional project ideas access to training compute power as a form of investment. Compute power enables developers to tackle more complex and resource-intensive use cases with increased efficiency, productivity, and performance. By being able to experiment with the capabilities of Falcon 40B, the best open-source LLM globally, developers can venture into uncharted territories, driving innovation and expanding the possibilities of AI solutions - at speed. Submissions are being welcomed from all over the world, and across all industries and sectors to find th

ees Europe 2023: Major Progress in New Battery Technologies7.6.2023 13:07:00 EEST | Press release

More and more electricity is being generated from renewable energies while the electromobility business is growing. Whether we are talking about sustainable power generation or electric mobility, one thing is key: Energy storage – especially battery storage. Manufacturers today primarily rely on lithium-based batteries. But now they are going one step further: The production of batteries is to become more environmentally friendly and the products more efficient, safer and cheaper. To this end, several manufacturers are now looking for alternatives – and they have found them. At ees Europe, the continent’s largest and most international exhibition for batteries and energy storage systems and the concurrent exhibitions, more than 950 suppliers will be presenting their latest products and solutions for the energy storage of the future. What’s more, attendees at the ees Europe Conference will learn first-hand where lithium-based batteries will continue to play out their advantages, but als

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom